BOULDER — Array BioPharma (Nasdaq: ARRY) experienced stock prices up 7 percent before the market opened following the announcement of positive data from clinical trials.
The third phase of clinical trials of its drug binimetinib combined with encorafenib showed positive results in patients with metastatic melanoma.
Member-owned not-for-profit Elevations Credit Union has a new branch in Midtown Fort Collins, featuring business bankers, commercial lenders and more.
Earlier this summer, Array filed new drug applications to the Food and Drug Administration for the combination of the two drugs.
At the time of publication, Array’s stock slid slightly, dropping from $11.82 when the market opened to $10.53 per share.